1. Home
  2. TXMD vs SRPT Comparison

TXMD vs SRPT Comparison

Compare TXMD & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TXMD
  • SRPT
  • Stock Information
  • Founded
  • TXMD 2008
  • SRPT 1980
  • Country
  • TXMD United States
  • SRPT United States
  • Employees
  • TXMD N/A
  • SRPT N/A
  • Industry
  • TXMD Biotechnology: Pharmaceutical Preparations
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TXMD Health Care
  • SRPT Health Care
  • Exchange
  • TXMD Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • TXMD N/A
  • SRPT N/A
  • IPO Year
  • TXMD N/A
  • SRPT 1997
  • Fundamental
  • Price
  • TXMD $1.10
  • SRPT $37.74
  • Analyst Decision
  • TXMD
  • SRPT Buy
  • Analyst Count
  • TXMD 0
  • SRPT 23
  • Target Price
  • TXMD N/A
  • SRPT $125.43
  • AVG Volume (30 Days)
  • TXMD 39.8K
  • SRPT 5.9M
  • Earning Date
  • TXMD 05-13-2025
  • SRPT 05-06-2025
  • Dividend Yield
  • TXMD N/A
  • SRPT N/A
  • EPS Growth
  • TXMD N/A
  • SRPT N/A
  • EPS
  • TXMD N/A
  • SRPT N/A
  • Revenue
  • TXMD $1,841,000.00
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • TXMD $427.09
  • SRPT $39.01
  • Revenue Next Year
  • TXMD N/A
  • SRPT $13.35
  • P/E Ratio
  • TXMD N/A
  • SRPT N/A
  • Revenue Growth
  • TXMD 53.55
  • SRPT 59.15
  • 52 Week Low
  • TXMD $0.70
  • SRPT $34.10
  • 52 Week High
  • TXMD $2.44
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • TXMD 32.08
  • SRPT 33.74
  • Support Level
  • TXMD $1.43
  • SRPT $36.96
  • Resistance Level
  • TXMD $1.51
  • SRPT $39.56
  • Average True Range (ATR)
  • TXMD 0.10
  • SRPT 2.06
  • MACD
  • TXMD -0.04
  • SRPT 0.98
  • Stochastic Oscillator
  • TXMD 8.33
  • SRPT 36.26

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: